TransCode Therapeutics Initiates Phase 2a Clinical Trial Of TTX-MC138 In Patients With Circulating Tumor DNA Following Treatment For Colorectal Cancer And Have No Radiographic Evidence Of Disease

Benzinga Newsdesk www.benzinga.com Neutral 72.9%

Neg 0% Neu 72.9% Pos 0%

Comments

No comments yet. Be the first!